Cancer specific immunity elicited with vaccines has traditionally focused on the activation of the CD8 cytolytic T lymphocyte (CTL) often involving direct stimulation of immunity using HLA-class I binding peptide epitopes. Recently it has become clear that activation of the CTL immune effector arm alone is insufficient to mediate an anticancer response. A major problem is that CD8 T cells alone can not be sustained without the concomitant activation of CD4 T helper (Th) cells. In fact, it is now widely recognized that the Th cell regulates nearly all aspects of the adaptive immune response. In addition, Th cells can recruit the innate immune system during immune augmentation. Therefore, the focus of the immune response in cancer has shifted away from activating CTL immunity alone to activating Th cell immunity alone or concurrently with CTL. Evidence suggests that activating the Th cell is sufficient to get a complete adaptive immune response because, once activated, the Th cell will elicit endogenous CD8 T cell and humoral immunity. In this review, we discuss the role of the Th cell in the adaptive immune response to cancer, how peptides that are capable of activation of Th cells are identified, and the clinical translation of newly identified candidate Th cell peptide epitopes to human cancer specific vaccines. Over the next decade, studies should begin to further define how we can manipulate the Th immune effector arm to achieve effective antitumor immunity.
I. INTRODUCTION
In recent years, the role of the Th cell response in the overall immune response has become increasingly clear. Th cells play a critical central role in the development of both humoral and cell-mediated adaptive immune responses to cancer. Due to the central role of Th cells, efforts have been applied to identifying the 9-31 amino acid peptide epitopes of tumor antigens that bind HLA-class II molecules and subsequently elicit the Th cell response. Several methods are now available to predict putative epitopes using mathematical algorithms, computational biology, and bioinformatics. In this article, some of the currently available methods of predicting epitopes are reviewed. The prediction of putative HLA-class II epitopes, however, represents only the first step in identifying peptides which are suitable for testing in cancer vaccines. Additional testing of the peptides is needed to ensure the likelihood that they will be immunogenic in humans in clinical testing. While several approaches have been used, one successful approach to identifying which of the putative epitopes will be immunogenic in cancer vaccines is to define whether there is an already existing immune response in patients with cancer. The presence of a pre-existent immune response suggests that tolerance is incomplete and/or that patients have already attempted to mount an immune response to the peptide. Cancer vaccines targeting Th cells have the potential to elicit a broad immune response against tumor antigens. This immune response may be important in a number of different clinical settings including preventing relapse in previously treated patients who are at high risk for relapse of their tumors. 
II. THE MANY ROLES OF CD4 HELPER T CELLS IN TUMOR IMMUNITY
Th cells are central to the development of immune responses for the protection against infection and possibly malignancy by activating antigen-specific effector cells (CTL and B cells) and recruiting cells of the innate immune system such as macrophages, eosinophils and mast cells [1] [2] [3] [4] [5] [6] [7] . The critical role for Th cells in tumor immunity has been postulated from many studies that have focused on the role of the Th cell in immunity against foreign pathogens (e.g. viruses, bacteria). Only recently, however, has the concept that tumor-specific immunity depends on Th cells been firmly established.
II.a. Tumor Antigen-specific Th Cells can be Activated by Either Antigen-Presenting Cells or Directly by HLAClass II-Expressing Tumors
The activation of the Th cell is likely an early step in the generation of a tumor-specific immune response and likely occurs when tumor antigens reach lymph nodes either as soluble antigen, through direct trafficking of tumor cells, or antigen-presenting cells that have encountered antigen in the tumor bed [8, 9] . During early immune activation, the latter process of antigen presenting cell (APC) delivery of antigens to lymph node T cells by dendritic cells (DC) is probably the predominant step since tumor cell migration (i.e. metastasis) is limited in early stage disease. Indeed, cancers are often infiltrated with dendritic cells early in the course of disease [10, 11] . For example, approximately 30% of node-negative early stage breast cancers have significant dendritic cell infiltration [12] . Dendritic cells can engulf tumor antigens and then travel to lymph nodes to directly activate Th cells [13] . Two predominant Th cell subtypes exist, Th1 and Th2, each with a unique role in the type of the global immune response elicited [14] . Th1 cells, characterized by secretion of IFN-and TNF-, are primarily responsible for activating and regulating the development of cell-mediated immunity [3] . Th2 cells, in contrast, favor a predominantly humoral response with induction of multiple isotypes of antibodies [14, 15] . For microbial pathogens, the development of either Th1 or Th2 lies in the interaction of the microbe or its products with early stage DC [16] . Microbial molecules have been identified that drive the maturation of DC into committed Th1-inducing or Th2-inducing DC, which promote the exclusive activation of Th1 or Th2 T cells, respectively [17, 18] . Th commitment is generally thought to be influenced by cytokines that are released from the mature DC. Th1 commitment relies on the local production of IL-12, and Th2 development is promoted by IL-4 in the absence of IL-12 [17] . It has also been shown that DC cell surface molecules such as OX-40 ligand can also influence Th differentiation [19] . However, currently it is unclear what the tumor cell determinants are that drive terminal differentiation of Th1-or Th2-inducing DC, if indeed they do exist.
In addition to DC-mediated activation of tumor cells there is some evidence that tumor cells can act directly as APC for activating Th cells [20, 21] . Of course, this would be dependent on tumor expression of HLA-class II. It is generally believed that most tumor cells do not express HLA-class II but there are some notable exceptions. Tumors that are associated with significant expression of HLA-class II are melanoma, breast, lung cancer, and osteosarcomas [22] . Expression of HLA-class II implies these tumors can directly activate Th cells. In general, it is thought that the activation of T cells requires co-stimulation through CD28, or other co-stimulatory molecules, concurrent with stimulation of the T cell receptor (TCR) [23] . In the absence of co-stimulation, tumor-antigen-specific T cells become anergic. Therefore, if HLA-class II-expressing tumor cells are to activate Th cells, co-stimulation would be required. The ligands of CD28, which are CD80 or CD86, are typically not expressed on tumor cells. In fact, it is the lack of co-stimulation that permits tumor cells to actively suppress immunity by rendering potential anti-tumor T cells anergic or even inducing T cell death by apoptosis [24] . However, other cells such as professional APCs, macrophages, or B cells often express one or both co-stimulatory molecules and could co-activate tumor-specific T cells. Since DC, macrophages, and B cells are present in the lymph nodes and often in the tumor bed it is likely that Th cell activation directly by tumor or by cross-priming can occur naturally to some extent.
While most models tend to support the hypothesis that a Th1 T cell immune response is the major mediator of antitumor immunity, Th2 T cell immunity, as will be discussed, may also be active. Recent theories strongly support the concept that the most effective immune response against either pathogens or tumors likely reflects a carefully orchestrated balance among many cell types involving both Th1 and Th2 T cells working in concert with other cells such as T cells including CTL and regulatory T cells [14] . As of yet, that balance required for effective tumor-specific immunity is unclear.
II.b. T Helper Cells Activate Tumoricidal Cells of the Innate Immune Effector Arm
Initially, it was thought that the primary role of Th cells for the tumor-specific immune response was to prime and sustain CTL immunity, although some early studies alluded to a broader role of Th cells. For example, studies by Dranoff and colleagues demonstrated that depletion of Th just prior to tumor challenge but following vaccine priming of CTL resulted in loss of the ability to reject tumor indicating a more immediate and direct role [25] . In another similar study, Levitsky showed that depletion of Th cells resulted in loss of the ability to reject HLA-class I negative tumors, the latter not being targets for CTL [26] . Hung and colleagues followed up by showing that CD8-knockout mice could be immunized to reject tumors in a CD4-dependent manner [6] . Since the tumors used in this latter study were HLA-class II-negative, the authors investigated how the CD4 T cells were able to mediate tumor rejection. They found that both Th1 and Th2 cells were important for the maximal antitumor response. Th1 cells produced IFN-which activated tumor macrophages to produce both nitric oxide and superoxide, both of which play an important role in tumor killing. Bonnotte and colleagues recently confirmed the importance of Th cells when it was demonstrated that Th cells removed, from animals immunized to reject poorly immunogenic tumors, could directly activate tumoricidal activity of macrophages [27] . Macrophages may also be directly involved in the IL-12-induced Th cell-dependent tumor rejection [28] . In the study conducted by Hung and colleagues it was also observed that the role of Th2 cells was to recruit and activate eosinophils that also were able to produce antitumor factors such as major basic protein (MBP) and eosinophil cationic protein (ECP) both of which can directly disrupt cell membranes and cause cell death [6, 29, 30 ]. These findings demonstrate that Th cells mediate their antitumor immune responses, at least in part, through modulation of effectors of the innate immune system.
II.c. Th Cells Directly Activate Tumor Antigen-Specific CTL
Th cells are important for the generation of adaptive immunity. Accumulated evidence suggests that CTL are important mediators of an antitumor response. Like Th cells, CTL recognize tumor antigen peptide fragments in the context of HLA molecules. Murine studies have demonstrated that CTL alone infused into tumor-bearing animals can mediate a direct antitumor effect [31] [32] [33] . However, this has not translated into therapeutic strategies because CTL are unable to support themselves, in vivo, in the absence of helper activity from Th cells [34, 35] . The need of help from Th cells was first discerned from studies investigating the generation, maintenance, and persistence of CTL in murine viral disease [3] . These studies revealed that the most important role of Th cells in the CTL response is in the maintenance phase. In the absence of Th, CTL activation remains normal in certain viral models such LCMV [36, 37] . However, in some mouse tumor models, it has clearly been shown that both Th1 and Th2 can directly initiate a CTLbased immune response. This was demonstrated by Fallarino and colleagues who showed that the infusion of either Th cell clones into tumor-bearing animals directly activated a CTL-mediated anti-tumor response [7] . Interestingly, there were no qualitative, only quantitative, differences between the Th1 and Th2 suggesting that there are multiple mechanisms boosting CTL immunity. One mechanism that has recently been described by Giuntoli and colleagues involves direct interaction between Th cells and CTL [38] . They observed in an in vitro model system that the function of tumor-specific CTL is enhanced by Th cell through costimulatory molecules present on the surface of the CTL such as CD27, CD134, and HLA-class II. In addition to direct contact, Th cell can directly activate CTL through cytokines such as IL-2 which can directly stimulate growth of CTL [39] . Th cells can also enhance CTL activity indirectly by activating other cell types that can subsequently influence CTL. For example, Th1 cells release IFN-which activates APC to upregulate molecules such as LMP2, LMP7, MECL, PA28, and HLA-class I, all of which contribute to increased antigen presentation to CTL [40] . Th1 induces the production of opsonizing antibodies that enhance the uptake of tumor cells into APC [6] . These activated APC can then directly present tumor antigen and promote expansion of tumor-specific CTL. In addition to activating and expanding CTL from the naïve T cell pool, studies also show that Th cell help is required for reactivation of memory CTL [41] . Overall, Th cells produce many factors which are able to, either directly or indirectly, influence the tumor antigen-specific CTL response.
II.d. T Helper Cells Directly Activate Tumor AntigenSpecific B Cells
Recent studies in murine models of cancer have demonstrated the importance of the humoral response working in conjunction with cell-mediated immunity in order to elicit an anti-tumor response. For example, Wolpoe and colleagues demonstrated in the neu-transgenic mouse model of breast cancer that the simultaneous injection of tumor antigen-specific antibodies and vaccine results in a collaborating immune response that is more efficacious than either antibody infusion or vaccination alone [42] . Similarly, successes with monoclonal antibodies as therapeutic agents to treat a variety of cancers such as breast and lymphoma has further stressed the importance of humoral immunity targeting cancer [43, 44] . Studies such as these have generated considerable interest in developing vaccine strategies that are aimed at eliciting an endogenous antibody response. Although Th2 cells have long been associated with strong humoral responses, Th1 cells are also capable of eliciting a strong, although distinctive from the Th2 cell-induced, antibody response. Th1 are important for the generation of opsonizing antibodies, a mechanism which facilitates the uptake and processing of antigens in APC such as DC and macrophages. Th2 cells do, however, play the predominant role in eliciting high level humoral immunity [45] . Th2 cells produce a number of different cytokines, including IL-10, IL-4, and IL-13, with well-described roles in B cell maturation, clonal expansion, and class-switching. Thus, as with other immune effector arms, the Th cell plays a critical role in the development of a B cell response.
II.e. T Helper Cells can Directly Kill Tumor Cells
Although the direct tumor cell killing effects of Th cells are less well characterized, some studies suggest that they are able to mediate cell death through the direct contact of the Th cell with the tumor cells. Th cells can induce the apoptosis of tumor cells through one of several related mechanisms. For example, Th cells can use the Fas/FasL pathway to directly induce apoptosis of tumor cells, although most studies indicate that this is not a preferred method for most cancers. In Burkitt's lymphoma, Fas/FasL-mediated tumor cell death appears to be a major mechanism of tumor growth control [46] . Thomas and Hersey revealed that Th cells mediate killing of melanoma and T cell lymphoma cells using a mechanism involving TNF-related apoptosis-inducing ligand (TRAIL) [47] . Th1 cells can also utilize a granzyme-perforin-dependent pathway for killing T lymphoma cells as recently shown by Echchakir and colleagues [48] . Thus, studies evaluating direct killing of tumor cells by Th cells have revealed that a number of different mechanisms could be involved, depending on the tumor type.
III. METHODS OF IDENTIFYING HLA-CLASS II EPITOPES

III.a. Characteristics of HLA-Class II Peptides
The most fundamental step in the activation of Th cells relies on the interaction of T cell receptor (TCR) with tumor antigen peptide-presenting HLA-class II molecules on target cells (e.g. DC, tumor cells, etc.). Compared to HLA-class I molecules, HLA-class II molecules are generally believed to be more permissive in the length and exact amino acid sequence of bound peptide. X-ray crystallography of HLAclass II molecules has revealed that the peptide binding groove is open-ended which contrasts the closed-ended binding groove of HLA-class I which can bind only nonamer amino acids [49, 50] . Various studies have indicated that HLA-class II molecules bind peptides with lengths ranging from 9-31 amino acids [49, 51, 52] . For example, in studies defining the T helper epitopes of tetanus toxoid, panels of overlapping peptides were screened for their ability to stimulate T cell proliferation in lymphocytes derived from tetanus-immune subjects. It was found that peptides of greater than 12 and less than 31 amino acids but typically in the range of 14 to 16 were most efficient for identifying region of the toxoid that contained binding epitopes [53] . Efforts over the last decade in defining epitopes, as well as allelic differences in HLA-class II, have resulted in the development of numerous physical and mathematical models that can aid in the identification of HLA-class II binding peptide ligands from tumor antigens.
III.b. Biochemical and Bioinformatics Techniques for HLA-Class II Binding Peptide Prediction
Traditional studies that have provided the basis for the development of epitope prediction models relied on either eluting peptides bound to specific HLA-class II molecules or screening panels of overlapping peptides derived from the study antigen. The first method, eluting and sequencing peptides bound to specific HLA-class II molecules from antigen-presenting cells, has been used to identify HLA-class II epitopes associated with insulin-dependent diabetes [54] , multiple sclerosis, and rheumatoid arthritis [55] , as well as from the melanoma tumor antigens tyrosinase [56] and gp100 [57] . The elution of peptides from specific HLA-class II molecules can be cumbersome and requires selection of specific HLA restriction elements for study. Others have identified T helper epitopes by screening panels of overlapping peptides derived from the study antigen using human lymphocytes. HLA-class II binding epitopes from tetanus toxoid [58] , diphtheria toxin [59] , as well as the MAGE-3 melanoma tumor antigen [60] and Kallikrein 4, a prostate cancer antigen [61] , have been identified by this method.
Kwok and colleagues have recently described a novel biochemical approach of rapid identification of HLA-class II-restricted Th cell peptides using an HLA-class II tetramerguided approach [62, 63] . Overlapping peptides that correspond to antigenic proteins are synthesized and combined into several pools. These peptide pools are then loaded onto HLA-class II tetramers which are subsequently used to stain T cells that have been stimulated with the peptide pools. Tetramer pools that stain the T cells are then further analyzed to define the bioactive peptides. The power of this technique was used to identify several immunogenic peptides derived from the HSV-2 VP16 protein. A disadvantage of this technique is that the cost of generating the peptide pools and acquiring the tetramers may be prohibitive. However, costs can be reduced by using this as a second step in an epitope identification program with predictive algorithms as a first step (discussed below) [62, 63] . A significant advantage of tetramer-guided epitope identification, however, is that the peptides that bind to both HLA-class II and TCR rather than just HLA-class II are identified.
Biochemical studies such as these have led to the development of several approaches for the prediction of HLA-class II binding peptides and are becoming more commonly used in place of the more laborious and costly biochemical techniques. There are several approaches that have been devised including (1) position-or motif-based approaches, (2) artificial neural networks (ANN), and (3) quantitative and virtual matrices. The development of all these strategies has completely relied on the extensive body of literature of the biochemical analysis of how and which peptides bind to HLA-class II molecules.
The position-based or motif-based approaches involve the identification of amino acid residues or regions (i.e. binding motifs) that are critical for anchoring the peptides into the HLA-class II cleft [64] . Additionally, amino acids in other positions can be identified that contribute to HLA-class II allelic specificity. These approaches rely nearly exclusively on the simple primary structure and position of critical amino acids. The position and side chain requirements for binding of peptides can be determined using random synthetic libraries as shown by Walden [65] . Hammer and colleagues found, using this approach, that 3 DR molecules, HLA-DRB1*0401, DRB1*1101, and DRB1*0101, all shared 2 anchor motifs at positions 1 and 4 of the peptide. In contrast, the allelic-specific secondary anchor residues were identified at position 6 [66, 67] . Compared to other methods, position-based methods such as these, however, have very high false negative rates because they are "all-or-none" [64] . An example of a commonly used predictive algorithm based on binding motifs is the Syfpeithi Database which is available on the internet at http://syfpeithi.bmi-heidelberg.com/ and described by Rammensee and colleagues [68] .
Our group has successfully predicted HLA-class II binding epitopes from HER-2/neu using another motif-based algorithm called TSites [69] . TSites combines 4 motif-based algorithms for identifying motifs according to charge and polarity patterns and tertiary structure, particularly related to amphipathic alpha helices [69] . Each of the 4 searching algorithms had empirically been successful in identifying a substantial proportion (50-70%) of helper T cell epitopes in foreign proteins [70, 71] . In our studies, analysis of HER-2/neu resulted in the identification of more than 40 peptides with a high potential to interact with HLA-class II [72] . As will be discussed in a subsequent section, several of the peptides identified in our studies were translated into a peptide-based vaccine for breast, ovarian, and lung cancer patients.
Several ANNs have been created that are able to predict HLA-class II binding T cell epitopes. ANNs are self-training programs that are able to find patterns associated with large data sets [73] . Honeyman and colleagues described the development of an ANN to predict potentially immunogenic peptides that bind DRB1*0401 (DR4) [73] . The ANN was trained using 338 peptides known to bind and 312 peptides known not to bind to DR4. The ANN was then tested against an array of 68 peptides, 16 amino acids in length, derived from the intracellular domain of the phosphatase PTP-IA2. The peptides were also examined for binding to DR4 experimentally as a comparison. The results revealed that this ANN had sensitivity (true positives/total positives) of approximately 55% and a selectivity of nearly 90%. This translated into an overall accuracy of approximately 78% which is very high compared to motif-based approaches which have accuracies of roughly 50% [54, 74] . Limitations of ANNs are that they can only be programmed to predict for a single HLA-class II allele. An example of an ANN available on the internet to predict binders of HLA-DR4, HLA-DR4Pred, is at http://www.imtech.res.in/raghava/ hladr4pred/ info.html.
Matrices, both quantitative and virtual, have also been established for the prediction of HLA-class II binding epitopes and involve the assessment of the contribution to binding of all amino acid at each position within the binding core of a peptide. Quantitative matrices are limited to a single HLA-class II allele while virtual matrices cover multiple alleles [64, 75] . Virtual matrices allow the prediction of promiscuous epitopes, which can bind to multiple HLA-class II alleles, which could be formulated to a broadly applicable vaccine. Matrices are generated from 'pocket profiles' which are the quantitative representation of the interaction of all amino acids within a single given HLAclass II peptide binding cleft [64] . A set of pocket profiles forms the virtual matrix used to determine binding epitopes. Bian and colleagues developed a virtual matrix software program called TEPITOPE [64] . TEPITOPE has been used to predict HLA-class II epitopes from numerous tumor antigens [76] [77] [78] . Consogno and colleagues used it to find promiscuous epitopes of MAGE3. TEPITOPE predicted 11 peptides that were subsequently tested in in vitro assays and all 11 peptides were found to bind to at least 3 different HLA DR alleles [78] . Nine of the eleven peptides were able to induce peptide-specific T cells derived from healthy subjects and melanoma patients. Of the 11, they found that 4 were naturally processed epitopes, each of which bound to 3-4 HLA DR molecules. Matrix-based algorithms can have accuracies ranging from 60-70% [79] . TEPITOPE software is readily available to not-for-profit research organizations through the website www.vaccinome.com. A HLA-class II prediction server, called ProPred, has been established based on the data from the original TEPITOPE publication [75, 80] . The ProPred Server is accessible at http://www.imtech. res.in/raghava/propred/.
Algorithms are continually being developed and improved as testing of predicted peptides continues. One potential method of improving epitope prediction would be to combine the distinct algorithms into a consensus strategy such as was recently postulated in a study evaluating whether or not there was a benefit to combining results from 3 independent algorithms [81] . Mallios speculated that there is a better chance that a peptide that was identified by all 3 of the algorithms has a better chance of being an authentic HLA-DR binder than a peptide that was identified by only 1 or 2 algorithms. His preliminary analysis seemed to indicate that such a consensus strategy may actually perform better. Nonetheless, it is clear that these algorithms have great potential for assisting in the designs of immune-based strategies targeting the antitumor Th cell.
IV. THE CLINICAL TRANSLATION OF T HELPER CELL VACCINES
While the different algorithms described above are useful for the identification of HLA-class II binding epitopes, they are neither able to address whether the peptides are able to bind to the TCR nor whether they are naturally processed within the cell. Additional efforts are needed to ascertain whether or not given predicted epitopes would be suitable for stimulating protective or therapeutic immunity. As previously discussed, our group used the motif-based algorithm, TSites, to identify putative helper peptides from HER-2/neu to formulate a vaccine for patients with advanced-stage breast and ovarian cancer. Our examination of HER-2/neu revealed 26 putative HLA-class II binding peptides, 15-18 amino acids in length [72] . In order to identify which of the peptides would be suitable for a vaccine, we surmised that if the peptides were T cell epitopes and naturally processed then they may be able to generate recall responses in patients with breast or ovarian cancer who had been exposed to high levels of HER-2/neu from their tumors. Therefore, the panel of 26 peptides was tested for T cell proliferation responses using standard thymidine incorporation assays. Nine of 26 peptides demonstrated the ability to elicit T cell responses, in vitro, in at least some of breast cancer patients evaluated [72] . There are a number of reasons why responses to the other 17 peptides were not detected. First, it is possible that the peptides did not bind to patients HLA-class II molecules and would therefore be algorithm-generated false positives. Secondly, tolergenic mechanisms may have eliminated all of the T cells that were capable of responding to these peptides. Lastly, the patients may not have had a recall T cell population. In the absence of suitable assays to distinguish these possibilities, we opted to use the nine peptides to which we could detect preexistent immunity and formulated these into 3 different vaccine preparations. The first vaccine targeted the extracellular domain of HER-2/neu and contained the 3 peptides HER-2/neu [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] , HER-2/neu 98-114 , and HER-2/neu 328-345 . The second targeted the intracellular domain of HER-2/neu and contained HER-2/neu 776-790 , HER-2/neu 927-941 , and HER-2/neu 1166-1180 . The final vaccine contained 3 peptides HER-2/neu 369-386 , HER-2/neu 688-703 , and HER-2/neu 971-984. The unique aspect of this final vaccine formulation was that each of the HLA-class II peptides contained an HLA-A2 (class I) binding peptide completely within the HLA-class II sequence. In a phase I clinical trial that evaluated the immunogenicity of all of the vaccine preparations, we found that over 90% of patients developed T cell immunity to their immunizing HER-2/neu HLA-class II peptides. Most importantly, over 60% developed HER-2/neu protein-specific immunity, indicating that each of the peptide vaccine formulations did contain peptides that were naturally processed. Thus, immunization with peptides resulted in the generation of T cells that could respond to protein processed by APC. Furthermore, at 1-year follow-up, immunity to the HER-2/neu protein persisted in over a third of patients. We concluded that immunity elicited by active immunization with HLA-class II epitopes included immunologic memory. An additional finding of this study was that epitope spreading was observed in the majority of patients and significantly correlated with the generation of HER-2/neu protein-specific T cell immunity. Epitope, or determinant spreading, is a phenomenon first described in autoimmune disease [82] and results from the generation of an immune response to some region of an immunogenic protein following the spread of that immunity to other areas of the protein or even to other antigens present in the environment. The same phenomenon, epitope spreading, was reported in a vaccine trial immunizing breast and ovarian cancer patients with autologous DC pulsed with MUC-1 or HER-2/neu peptides [83] . Epitope spreading may represent the ability of the initial immune response to create a microenvironment at the site of the tumor that enhances endogenous local immunity [84] . Despite the generation of detectable immunity against the self-protein HER-2/neu and the development of epitope spreading none of the patients in the studies described above developed any evidence of autoimmunity directed against tissues expressing basal levels of HER-2/neu such as skin, liver, and digestive tract epithelium.
It was also observed that the outcome of vaccination with the HLA-class II epitopes that encompassed the HLA-A2 motifs was noteworthy in relationship to a second study which ran concurrently. This second study involved a more classic immunization of HLA-A2 patients with a single HLA-A2 binding peptide HER-2/neu 369-377 [85] . The differences in the immune response generated to HER-2/neu 369-377 were significant. Patients immunized with the helper epitopes generated both greater magnitude and greater durability of T cell immunity to the HLA-A2 epitope. The higher HER-2/neu 369-377 responses correlated with higher responses to the longer Th epitope that fully encompassed it. Similarly, those with a more vigorous Th response maintained the magnitude of the HLA-A2 peptide specific response longer than 1 year. HLA-A2 peptide-specific T cells derived from these patients could lyse HER2 overexpressing HLAmatched cells [86] . Patients immunized with HER-2/neu 369-377 alone in a manner identical to that of the helper peptide vaccine developed low-level short-lived peptide specific immunity [85] . These data suggest that the magnitude and longevity of the CTL responses were enhanced with Th cell generation.
Lastly, we subsequently tested each of the 9 peptides, from our original peptide formulations, for their ability to bind to various HLA-DR molecules using in vitro binding assays [87] . From these studies, it was observed the affinity of the in vitro peptide binding correlated with the in vivo immunogenicity (i.e. the percentage of patients who responded). The 3 peptides that emerged as the most immunogenic were HER-2/neu 98-114, HER-2/neu 369-386, and HER-2/neu 776-790. Each of these peptides bound with high affinity to 5 or more of the 14 HLA-DR alleles tested in vitro. These results indicate that an additional step of testing of in vitro binding may prove useful in narrowing down large sets of potential HLA-class II binding peptides.
V. CONCLUSIONS AND FUTURE DIRECTIONS
Th cells play a critical role in regulating all aspects of adaptive immunity. Investigations over the last decade into how Th cells are activated by HLA-class II-peptide complexes have resulted in the development of technology such as computer algorithms. Newer algorithms can predict binding with accuracies approaching 80-90%. Clinical trials have clearly indicated that cancer patients can be immunized against self-tumor antigens using predicted HLA-class II binding peptides that have been screened for evidence of natural presentation. Augmenting Th immunity targeting cancer, alone or in combination with CTL, will likely prove of greater benefit than augmenting immunity to CTL alone due to the central regulatory role of Th cell. gratefully acknowledge the expert editorial assistance of Marsha Weese. 
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